Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling

Kailu Wang,Ho-Man Shum,Carrie Ho-Kwan Yam,Yushan Wu,Eliza Lai-Yi Wong,Eng-Kiong Yeoh
DOI: https://doi.org/10.1007/s40258-024-00912-1
2024-09-11
Applied Health Economics and Health Policy
Abstract:Patients may get more treatment options with off-label use of drugs while exposed to unknown risks of adverse events. Little is known about the public or demand-side perspective on off-label drug use, which is important to understand how to use off-label treatment and devise financial assistance. This study aimed to quantify public preference for off-label cancer treatment outcomes, process, and costs, and perceived importance of associated adverse events.
health care sciences & services,health policy & services,economics
What problem does this paper attempt to address?